Theravance Biopharma TBPH Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$4.93M-108% | $61.02M+1,588% | $3.62M-93.4% | $54.84M+504% | -$13.58M+12.5% | ||
| $381K-4.5% | $399K-1.5% | $405K-1.0% | $409K-1.0% | $413K-2.1% | ||
| $4.5M+0.5% | $4.48M-2.1% | $4.58M+0.7% | $4.54M-6.8% | $4.88M-16.3% | ||
| -$3M— | —— | —— | -$10.69M-477% | -$1.85M+71.9% | ||
| -$1.47M-514% | $355K-34.0% | $538K+173% | -$733K-542% | $166K-78.9% | ||
| -$4.87M— | —— | $3.61M+13.0% | $3.19M+311% | -$1.51M-151% | ||
| -$1.03M— | —— | $413K-66.8% | $1.25M+477% | -$330K— | ||
| -$69K— | —— | —— | $1K-98.5% | $68K+112% | ||
| -$42K— | $0-100% | $22K-35.3% | $34K-12.8% | $39K— | ||
| $1.06M-4.6% | $1.11M+10.5% | $1M+6.6% | $940K-2.7% | $966K-8.3% | ||
| -$2.2M-16.2% | -$1.89M-1.6% | -$1.86M-9.6% | -$1.7M-2.1% | -$1.66M-134% | ||
| $73.28M— | —— | —— | $208.07M+383% | $43.04M+4,872% | ||
| $43.41M-33.1% | $64.93M-48.0% | $124.75M+121% | $56.57M+2,775% | $1.97M-94.8% | ||
| $96M+46.5% | $65.53M+167% | $24.5M+20.4% | $20.35M-37.6% | $32.6M-18.6% | ||
| $52.59M— | $0+100% | -$100.25M-176% | -$36.26M-218% | $30.63M+95.3% | ||
| $241K— | —— | —— | —— | $20K-33.3% | ||
| $5.82M+194% | $1.98M+192% | $678K+34.8% | $503K-42.4% | $874K+65.5% | ||
| -$5.58M-274% | -$1.49M-273% | -$400K+20.5% | -$503K+41.1% | -$854K-134% | ||
| $120.3M— | —— | —— | $171.31M+135% | $72.82M— | ||
| -$351K-106% | $6.21M-51.4% | $12.77M+43.5% | $8.9M+222,425% | $4K-95.9% | ||
| $602K-54.0% | $1.31M+69.9% | $771K+82.7% | $422K+29.1% | $327K-58.1% | ||
| -$2.2M-16.2% | -$1.89M-1.6% | -$1.86M-9.6% | -$1.7M-2.1% | -$1.66M-134% | ||
| -$69K— | —— | —— | $1K-98.5% | $68K+112% | ||
| -$1.03M— | —— | $413K-66.8% | $1.25M+477% | -$330K— | ||
| —— | —— | —— | —— | -$73K+86.1% | ||
| -$1.67M-305% | $814K-31.0% | $1.18M-22.2% | $1.52M+1,124% | -$148K+95.7% | ||
| -$50M— | —— | —— | —— | -$50M— | ||
| -$29.95M-210% | $27.27M+847% | -$3.65M-156% | $6.57M+313% | -$3.09M-294% | ||
| -$314K-1,221% | $28K— | —— | $3K-92.9% | $42K-42.5% | ||
| —— | $582K+1.6% | $573K-13.6% | $663K+3.1% | $643K0.0% | ||
| $1.06M-4.6% | $1.11M+10.5% | $1M+6.6% | $940K-2.7% | $966K-8.3% | ||
| $381K-4.5% | $399K-1.5% | $405K-1.0% | $409K-1.0% | $413K-2.1% | ||
| -$42K— | $0-100% | $22K-35.3% | $34K-12.8% | $39K— | ||
| $1.47M-77.4% | $6.52M+379% | $1.36M+3.0% | $1.32M+2.8% | $1.29M-64.7% | ||
| $96M+46.5% | $65.53M+167% | $24.5M+20.4% | $20.35M-37.6% | $32.6M-18.6% | ||
| -$2.2M-16.2% | -$1.89M-1.6% | -$1.86M-9.6% | -$1.7M-2.1% | -$1.66M-134% | ||
| —— | —— | —— | —— | —— | ||
| -$351K-106% | $6.21M-51.4% | $12.77M+43.5% | $8.9M+222,425% | $4K-95.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Theravance Biopharma generate?
- Theravance Biopharma (TBPH) generated $323.5M in operating cash flow over the trailing twelve months.
- Where does Theravance Biopharma's cash flow data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
